A detailed history of Reliant Investment Management, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Reliant Investment Management, LLC holds 1,387 shares of LLY stock, worth $1.06 Million. This represents 0.62% of its overall portfolio holdings.

Number of Shares
1,387
Previous 1,328 4.44%
Holding current value
$1.06 Million
Previous $1.2 Million 2.16%
% of portfolio
0.62%
Previous 0.6%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$772.14 - $960.02 $45,556 - $56,641
59 Added 4.44%
1,387 $1.23 Million
Q2 2024

Jul 22, 2024

SELL
$724.87 - $909.04 $7,248 - $9,090
-10 Reduced 0.75%
1,328 $1.2 Million
Q4 2023

Jan 24, 2024

SELL
$525.19 - $619.13 $23,108 - $27,241
-44 Reduced 3.18%
1,338 $779,000
Q3 2023

Oct 13, 2023

SELL
$434.7 - $599.3 $21,735 - $29,964
-50 Reduced 3.49%
1,382 $742,000
Q1 2023

Apr 20, 2023

SELL
$310.63 - $364.82 $21,744 - $25,537
-70 Reduced 4.66%
1,432 $491,000
Q4 2022

Jan 19, 2023

SELL
$321.55 - $374.67 $41,801 - $48,707
-130 Reduced 7.97%
1,502 $0
Q3 2022

Oct 19, 2022

BUY
$296.48 - $337.87 $93,391 - $106,429
315 Added 23.92%
1,632 $528,000
Q4 2021

Jan 18, 2022

SELL
$224.85 - $279.04 $37,100 - $46,041
-165 Reduced 11.13%
1,317 $364,000
Q4 2020

Feb 16, 2021

BUY
$130.46 - $172.63 $7,697 - $10,185
59 Added 4.15%
1,482 $250,000
Q3 2020

Nov 13, 2020

BUY
$146.22 - $169.13 $24,126 - $27,906
165 Added 13.12%
1,423 $211,000
Q2 2020

Aug 28, 2020

BUY
$136.42 - $164.18 $171,616 - $206,538
1,258 New
1,258 $207,000
Q2 2018

Aug 06, 2018

SELL
$75.7 - $86.88 $2.65 Million - $3.04 Million
-34,979 Closed
0 $0
Q1 2018

May 31, 2018

BUY
$74.21 - $87.6 $37,476 - $44,238
505 Added 1.46%
34,979 $2.71 Million
Q4 2017

Feb 07, 2018

BUY
$81.94 - $87.89 $2.82 Million - $3.03 Million
34,474
34,474 $2.91 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $730B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Reliant Investment Management, LLC Portfolio

Follow Reliant Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Reliant Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Reliant Investment Management, LLC with notifications on news.